相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article
Immunology
Yaki Saciuk et al.
Summary: A retrospective cohort study in Israel showed that a third dose of the BNT162b2 vaccine provides added protection against SARS-CoV-2 infection, especially for those vaccinated six months ago. The vaccine's effectiveness was found to be 92.9% in terms of prevention of infection, highlighting the importance of booster doses in maintaining immunity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Mayan Gilboa et al.
Summary: This study reports a rapid and broad immune response following the third dose of the BNT162b2 vaccine in individuals aged over 60. The levels of antibodies post-third dose were significantly higher than post-second dose.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Peter B. Gilbert et al.
Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: The study shows that receiving a booster dose of the BNT162b2 vaccine can significantly lower the rates of confirmed Covid-19 and severe illness, as well as reduce mortality among individuals aged 60 and above.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Anne M. Hause et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Article
Infectious Diseases
Cristina Menni et al.
Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.
LANCET INFECTIOUS DISEASES
(2021)
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
T. Pilishvili et al.
Summary: The BNT162b2 and mRNA-1273 vaccines were highly effective in preventing symptomatic Covid-19 in U.S. health care personnel, with vaccine effectiveness of 77.6% to 96.3%. The effectiveness was consistent across different subgroups defined by age, race and ethnic group, underlying conditions, and patient contact levels, indicating the vaccines were effective for preventing Covid-19 in those at risk and in disproportionately affected groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Critical Care Medicine
Yaniv Lustig et al.
Summary: The study assessed early antibody responses after Pfizer-BioNTech BNT162b2 COVID-19 vaccine in Israeli healthcare workers. Results showed that 77% of participants had positive IgG response at week 3 after the first vaccine dose, with lower responses in older and immunosuppressed individuals. Timely second dose vaccinations are particularly important for these populations to enhance antibody responses and reduce breakthrough infections.
LANCET RESPIRATORY MEDICINE
(2021)